Insights

Gathering insights about Mend…

Similar companies to Mend

Mend Tech Stack

Media & News

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why
Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company traded as low as $1.95 and last traded at $1.96. Approximately 72,560 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 143,648 shares. The stock had previously closed at $1.97. Analysts
Nov 22, 2025 | www.defenseworld.net
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA , Nov. 19, 2025 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects. In collaboration with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating the distinctive characteristics of AL001.
Nov 19, 2025 | www.prnewswire.com
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced it will have a poster presentation at the Military Health System Research Symposium (“MHSRS”), being held from August 4-7, 2025, in Orlando, Florida. “Our upcoming poster presentation at MHSRS 2025 represents an exceptional opportunity to spotlight our cutting-edge innovation and its transformative potential for active-duty service members and military veterans,” said Stephan Jackman, Chief Executive Officer of Alzamend.
Jul 28, 2025 | www.globenewswire.com
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General Hospital In June 2025, Alzamend completed the final closing of its $5 million private placement months ahead of schedule ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission. Alzamend has strengthened its financial position, reflecting a strategic focus on fiscal prudence and effective capital management.
Jul 23, 2025 | www.globenewswire.com
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “Agreement”) with a sophisticated investor (the “Investor”), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase shares of Alzamend's common stock for a total purchase price of up to $5 million, less a five percent (5%) discount (the “Financing”) in seven monthly tranche closings (a “Tranche Closing”), starting in April 2025, with the Investor having the ability, in its sole discretion, to purchase Preferred Stock prior to the dates set for each Tranche Closing.
Jun 16, 2025 | www.globenewswire.com
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
May 29, 2025 | www.globenewswire.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
May 19, 2025 | www.globenewswire.com

Mend's Email Address Formats

Mend uses at least 2 format(s):

Mend Email Formats	Example	Percentage
First@mendpoverty.org	John@mendpoverty.org	90%
FLast@mendpoverty.org	JDoe@mendpoverty.org	4%
Last@mendpoverty.org	Doe@mendpoverty.org	4%
FirstLast@mendpoverty.org	JohnDoe@mendpoverty.org	2%
First.Last@mendlondon.blogspot.com	John.Doe@mendlondon.blogspot.com	100%

Frequently Asked Questions

What is Mend's stock symbol?

Mend is a publicly traded company; the company's stock symbol is ALZN.

What is Mend's official website and social media links?

Mend's official website is mendlondon.blogspot.com and has social profiles on LinkedIn.

What is Mend's NAICS code?

Mend's NAICS code is 921 - Executive, Legislative, and Other General Government Support.

How many employees does Mend have currently?

As of December 2025, Mend has approximately 39 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Physiotherapist: K. H.Merchandiser: M. G. J.Physician Assistant: K. D.. Explore Mend's employee directory with LeadIQ.

What industry does Mend belong to?

Mend operates in the Public Policy Offices industry.

What is Mend's email format?

Mend's email format typically follows the pattern of First@mendpoverty.org. Find more Mend email formats with LeadIQ.

Mend

Q: What is Mend's official website and social media links?

Mend's official website is mendlondon.blogspot.com. Mend has social profiles on LinkedIn.

Q: How many employees does Mend have currently?

Mend has approximately 39 employees.

Public Policy Offices11-50 Employees

Learn about working at Mend. Join LinkedIn today for free. See who you know at Mend, leverage your professional network, and get hired.

Company Overview

Website: mendlondon.blogspot.com
Stock Symbol: ALZN
NAICS Code: 921 - Executive, Legislative, and Other General Government Support
Employees: 11-50

Media & News

Funding & Financials

$250M$500M
Mend's revenue is estimated to be in the range of $250M$500M

Funding & Financials

$250M$500M
Mend's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Mend

Updox

Relatient

Vital Interaction

Luma Health

WellnessIQ

Brevity

Zocdoc

Klara

Everseat

Mend Tech Stack

Media & News

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Mend's Email Address Formats

Frequently Asked Questions

What is Mend's stock symbol?

What is Mend's official website and social media links?

What is Mend's NAICS code?

How many employees does Mend have currently?

What industry does Mend belong to?

What is Mend's email format?

Mend

Company Overview

Media & News

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?